Effects of zoledronic phosphates on dehydroepi and rosterone sulfate in women with postmenopausal osteoporosis

PAN Chunyan; ZHANG Yinxing

doi:10.3969/j.issn.1002-7386.2016.15.011

Abstract：Objective To observe the effects of zoledronic phosphate on dehydroepiandrosterone sulfate ( DHAS) in women with postmenopausal osteoporosis .Methods The 80 woman patients with postmenopausal osteoporosis who were admitted and treated in our hospital from February 2014 to May 2015 were randomly divided into observation group ( n =40) and control group ( n =40).The patients in control group were treated by calcitriol soft capowan ,however,the patients in control group ,on the basis of control group ,were treated by zoledronic phosphate .The therapeutic effects , contents of DHAS , osteodynia symptom, adverse reactions were observed and compared between two groups .Results After treatment ,the total effective rate in observation group was significantly higher than that in control group (92.50% vs 72.50%, P <0.05).At the beginning, there were no significant differences in the contents of DHAS between two groups ( P >0.05).After 60-day treatment,the contents of DHAS in observation group were obviously increased ,after 90-day treatment, the contents of DHAS in observation group were significantly increased ,as compared with those in control group ( P <0.05).After treatment the remission rate of osteodynia in observation group was significantly higher than that in control group (92.50%vs 75.00%,P<0.05).The incidence of adverse reactions in observation group was significantly lower than that in control group (7.50%vs 57.50%, P <0.05).Moreover the bone density in observation group was significantly increased ,as compared with that in control group ( P <0.05).Conclusion The zoledronic phosphate is effective in treating postmenopausal osteoporosis ,which can effectively increase the contents of DHAS and reduce the incidence of adverse reactions ,with better safety .